ABSTRACT
Cisplatin is a potent antitumor agent that is useful in chemotherapy of various types of cancers. Currently, nephrotoxicity limits its usefulness. The main mechanism responsible for nephrotoxicity is oxidative stress with associated inflammation. This study was to evaluate the protective effect of zinc sulphate on cisplatin-induced nephrotoxicity in cancer patients. Twenty eight patients were participated in the study and were randomized into two groups. Patients in group I (N=14) received six cycles of cisplatin based regimen every 21 days. Patients in group II (N=14) received zinc sulphate in addition to cisplatin based regimen. Serum cystatin C and cystatin C-based GFR were measured at base line and 21 days after 1, 2, 4 and 6 cycles while urinary malondialdehyde and IL-18 were measured at base line and 1 day after 1, 2, 4 and 6 cycles of cisplatin based regimen. Zinc sulfate addition to cisplatin in group II significantly (P<0.05) ameliorated the cisplatin-induced increment in serum cystatin C, urinary malondialdehyde and IL-18 and the cisplatin-induced decline in cystatin C-based GFR that were demonstrated in group I. The significant protective effect of zinc sulfate on cisplatin-induced nephrotoxicity may be through its antioxidant and anti-inflammatory action.
(FULL ARTICLE LINK) Read more ...
30-11-2014.
|
|
|
